Trial for BRAF-mutant melanoma spread to the brain
Treatments studied
Part of Brain & nervous system, Cancer, Skin clinical trials.
This Phase 2 study tests whether a 3-drug plan (encorafenib + binimetinib + nivolumab) works better than ipilimumab + nivolumab for melanoma that has spread to the brain. If you qualify, you’ll get either treatment and have frequent brain scans to track how well it controls the tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have melanoma that has spread to the brain (confirmed by pathology tests).
- Your melanoma must be BRAF-V600 mutant, confirmed by a certified lab test.
- You must have a recent brain MRI within 28 days showing at least one measurable brain tumor (≥ 0.5 cm) that hasn’t been recently treated with radiation or hasn’t grown after prior radiation.
- You may take a limited steroid dose for brain swelling (up to 8 mg dexamethasone per day) and it must not have been higher than that for at least 7 days.
- Your general health must be good enough (Zubrod performance status 2 or less), and you must be able to swallow and keep pills down.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests two targeted medicines (binimetinib and encorafenib) for melanoma that has spread to the brain. It focuses on people whose tumor has a specific BRAF V600 mutation and who have brain metastases that are progressing or need treatment.
This Phase 1 trial tests a combination of targeted cancer medicines to treat melanoma that has spread or cannot be removed by surgery. It is for people whose tumor has a specific BRAF mutation, and who have either stayed stable on a prior targeted treatment or no longer respond to it.
This trial tests a combination of two or three drugs (defactinib, avutometinib, with or without encorafenib) to shrink brain tumors that started from skin melanoma. It may be an option for people whose melanoma has a specific genetic change and who have already tried immunotherapy.
This trial tests a combination of targeted drugs (encorafenib and binimetinib) followed by immunotherapy (cemiplimab and fianlimab) for people with advanced melanoma that has spread to the brain and is causing symptoms. The goal is to see if this approach can shrink tumors and help control the disease.
This trial tests a combination of three immunotherapy drugs (relatlimab, nivolumab, and ipilimumab) for people with melanoma that has spread to the brain. It aims to see if this treatment can shrink brain tumors and improve outcomes.
This trial studies whether giving the immunotherapy drug nivolumab together with targeted brain radiation (not whole-brain radiation) helps people with melanoma that has spread to the brain. It aims to improve brain control while keeping side effects manageable.
Hear when a new Clinical Stage IV Cutaneous Melanoma AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.